I. Partie, Prévention des TVP en chirurgie orthopédique majeure, p.57

.. Posologie-et-mode-d-'administration, 69 3.2.2.5 Mode d'administration et surveillance biologique, p.71

I. Études-de-phase, Les effets indésirables les plus fréquemment observés sont comme pour les autres molécules, le risque de saignements et l'anémie. De plus, quelques rares cas d'élévation des transaminases hépatiques ont été décrits

J. Sampol, Manuel d'hémostase. Editions scientifiques et médicales, pp.37-70, 1995.

R. S. Diaporama, Cascade de la coagulation et inflammation

H. Lévesque, Accidents thrombotiques chez les patients artéritiques atteints d'une anomalie de l'hémostase

H. Antagonistes-de-la-vitamine and K. , Régulation physiologique de la coagulation et ses différents acteurs

C. Lapandry and F. Lapostolle, Accidents thromboemboliques et voyages aériens, pp.81-96, 2004.

L. 'état-de-santé-de-la-population-en-france, Indicateurs associés à la loi relative à la politique de santé publique, Objectif, vol.72, pp.268-271, 2009.

F. Rosendaal, Venous Thrombosis: The Role of Genes, Environment, and Behavior, Hematology, vol.2005, issue.1
DOI : 10.1182/asheducation-2005.1.1

S. Sevitt, The structure and growth of valve-pocket thrombi in femoral veins, Journal of Clinical Pathology, vol.27, issue.7
DOI : 10.1136/jcp.27.7.517

J. Hirsh and J. Hoak, Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professional, Circulation, issue.93, pp.2212-2245, 1996.

F. Turkstra, M. Koopman, and H. Büller, The treatment of deep vein thrombosis and pulmonary embolism

. Embolie-pulmonaire, http://www.livretsante.com/mes pages/articles.php?arti=1933&PHPSESSID=c19ca1015835f9b675598e5d30cb4fed#

F. Anderson, . Jr, H. Wheeler, and R. Goldberg, A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study, Arch Intern Med, issue.5, pp.151-933, 1991.

J. Heit, M. Silverstein, and D. Mohr, Risk Factors for Deep Vein Thrombosis and Pulmonary Embolism, Archives of Internal Medicine, vol.160, issue.6, pp.160-809, 2000.
DOI : 10.1001/archinte.160.6.809

S. Goldhaber, F. Grodstein, and M. Stampfer, A prospective study of risk factors for pulmonary embolism in women

L. Ministère-des-affaires-sociales-et-de and . Santé, Communiqué de presse du 20 septembre 2012, 2012.

M. Donati, Cancer and Thrombosis, Pathophysiology of Haemostasis and Thrombosis, vol.24, issue.2, pp.128-131, 1994.
DOI : 10.1159/000217092

C. Bernstein, J. Blanchard, and D. Houston, The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study

F. Magro, M. Dinis-ribeiro, and F. Araujo, High prevalence of combined thrombophilic abnormalities in patients with inflammatory bowel disease, European Journal of Gastroenterology & Hepatology, vol.15, issue.11
DOI : 10.1097/00042737-200311000-00002

. La-revue-prescrire, Neuroleptiques : Thromboses veineuses et embolies pulmonaires ; À prendre en compte dans les choix et le suivi, pp.588-589, 2006.

D. Danilenko-dixon, J. Heit, and M. Silverstein, Risk factors for deep-vein thrombosis and pulmonary embolism during pregnancy or postpartum : a population based, case-control study

N. Rosencher, K. Boucebci, and G. Menichella, Orthopaedic Surgery Transfusion Haemoglobin European Overview: the OSTEO study (extended abstract), Transfusion Clinique et Biologique, vol.8, issue.3
DOI : 10.1016/S1246-7820(01)00124-0

D. Chanzy and N. Paris, Différentes phases de l'intervention de la pose d'une prothèse totale de hanche

D. Chanzy and N. Paris, Différentes phases de l'intervention de la pose d'une prothèse totale de genou

A. Nicolaides, Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance withe the scientific evidence

. La-thrombose-asymptomatique-en-orthopédie, outil méthodologique ou critère intermédiaire ? Sang Thrombose Vaisseaux. Mini-revues, pp.341-346, 2002.

R. White, P. Romano, and H. Zhou, Incidence and Time Course of Thromboembolic Outcomes Following Total Hip or Knee Arthroplasty, Archives of Internal Medicine, vol.158, issue.14, pp.1525-1531, 1998.
DOI : 10.1001/archinte.158.14.1525

J. Grady-benson, C. Oishi, and P. Hanson, Postoperative surveillance for deep venous thrombosis with duplex ultrasonography after total knee arthroplasty., The Journal of Bone & Joint Surgery, vol.76, issue.11
DOI : 10.2106/00004623-199411000-00008

A. Abdel-salam and K. Eyres, Effects of tourniquet during total knee arthroplasty. A prospective randomised study, The Journal of Bone and Joint Surgery. British volume, vol.77, issue.2
DOI : 10.1302/0301-620X.77B2.7706340

. Brochure-de-la-ligue-française-contre-la-maladie-veineuse-thromboembolique, Article 44

B. Dixon, J. Santamaria, and D. Campbell, Coagulation Activation and Organ Dysfunction Following Cardiac Surgery, Chest, vol.128, issue.1, pp.128-229, 2005.
DOI : 10.1378/chest.128.1.229

G. Hinterhuber, K. Bohler, and H. Kittler, Extended monitoring of hemostatic activation after varicose vein surgery under general anesthesia

. Anesthésie-en-orthopédie, Congrès national d'anesthésie et de réanimation, pp.365-390, 2007.

P. Wells, D. Anderson, and M. Rodger, Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis

M. Samama, H??t??rog??n??it?? pharmacologique des nouveaux anticoagulants, Journal des Maladies Vasculaires, vol.36, pp.36-46, 2011.
DOI : 10.1016/S0398-0499(11)70002-6

B. Boneu and J. Casenave, Introduction à l'étude de l'hémostase et de la coagulation, Seconde édition, vol.259, 1997.

M. Levine, G. Raskob, and S. Landefeld, Hemorrhagic complications of anticoagulant treatment, Chest, pp.119-108, 2001.

. Fondaparinux, a synthetic pentasaccharide : the first of a new class of antithrombotic agents the selective for factor Xa inhibitor, Cardiovasc Drug Review, pp.20-37, 2002.

J. Lormeau and J. Herault, The effect of the synthetic pentasaccharide SR9017A/ORG31540 on thrombin generation ex vivi is uniquely du to ATIII-mediated neutralization of factor Xa

J. Walenga, The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity, Thrombosis Research, vol.51, issue.1
DOI : 10.1016/0049-3848(88)90279-4

E. Petzborn, Rivaroxaban: A New Oral Factor Xa Inhibitor

P. Fontana and H. Bounameaux, Nouveaux antithrombotiques : état des lieux en, 2009.

E. Petzborn, Inhibition of thrombin generation by rivaroxaban BAY 59-7939-an oral, direct Factor Xa inhibitor-in human plasma

L. Bellamy, Experience d'une année de prescription du Xarelto®

D. La-communication-de-mouret and P. , Revue de chirurgie orthopédique et réparatrice de l'appareil locomoteur, pp.96-101, 2010.

. Commission-de-transparence-has, Avis du 14 Mars 2012 relatif à Xarelto®

I. Troconiz, Population Pharmacokinetic Analysis of the New Oral Thrombin Inhibitor Dabigatran Etexilate (BIBR 1048) in Patients Undergoing Primary Elective Total Hip Replacement Surgery, The Journal of Clinical Pharmacology, vol.33, issue.3
DOI : 10.1540/jsmr.33.37

P. Mismetti and S. Laporte, Dabigatran : donn??es pharmaco-cliniques, Annales Fran??aises d'Anesth??sie et de R??animation, vol.28, issue.9
DOI : 10.1016/S0750-7658(09)72459-1

. France, Mentions légales et complètes ELIQUIS®

. Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict, Expert Opin Investig Drugs, pp.17-1937, 2008.

A. Turpie, For the pentasaccharide investigators. A synthetic pentasaccharide for the prevention of deep vein thrombosis after total hip remplacement. NEJM, pp.344-619, 2001.

B. Eriksson, Rivaroxaban versus enoxaparin for thromboprophylaxisafter hip arthroplasty, NEJM, vol.26, issue.358, pp.2765-2775, 2008.
DOI : 10.1056/nejmoa0800374

M. Lassen, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. NEJM, pp.358-2776, 2008.

M. Lassen, ADVANCE-2 investigators

. La-revue-prescrire, Tome 29 N°307 : 327, pp.326-329, 2009.

E. Eerenberg, Reversal of rivaroxaban and dabigatran by prothrombine complex concentrate. A randomized, placebo-controlled, crossover stydy in healthy subjects, Circulation, 2011.